Journal article
The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer
Abstract
Lung cancer is a highly heterogeneous disease often driven by well-characterized driver mutations. Although the best studied are common alterations in the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) oncogenes, rapid advances in molecular characterization has led to the development of novel therapeutics that inhibit additional oncogenic alterations in advanced NSCLC. The literature search identified 62 eligible …
Authors
Melosky B; Wheatley-Price P; Juergens RA; Sacher A; Leighl NB; Tsao M-S; Cheema P; Snow S; Liu G; Card PB
Journal
Lung Cancer, Vol. 160, , pp. 136–151
Publisher
Elsevier
Publication Date
October 2021
DOI
10.1016/j.lungcan.2021.06.002
ISSN
0169-5002